The latest news, announcements and press releases from Circio.
Oslo, Norway 21 January 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces that it has entered a partnership with 4basebio PLC of Cambridge, UK, for joint development and in vivo delivery testing of synthetic circVec DNA vectors.
“The circVec technology achieves up to 70 times prolonged RNA half-life and 15-fold increase in protein levels vs. standard mRNA-based expression in vivo using plasmid DNA,” said Dr. Thomas Hansen, CTO of Circio. “We have therefore now partnered with 4basebio, a world-leader in next-generation DNA vectors for therapeutic applications. Combining 4basebio´s vector and delivery expertise with Circio´s circVec powerful expression technology has the potential to create a durable, repeat-dosable, non-viral platform for future synthetic DNA gene therapies.”
Oslo, Norway, 13 May 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing circular RNA-based gene therapy, today announces that it has presented two posters that demonstrate in vivo proof-of-concept for its powerful and differentiated circVec platform approach to gene therapy. The two posters were presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 annual meeting 7-11 May in Baltimore, USA
This is the News section of the company profile page for Circio on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
